TABLE 1

Bioavailability and intestinal availability for CYP3A and P-gp substrates

CompoundDoseivDosepoRbFFhaObserved FaFgReference
mgmg
Felodipine2.52.50.70.1520.3770.240bEdgar et al., 1985; Uchimura et al., 2010c;
Midazolam260.8240.2530.6380.396Tsunoda et al., 1999; Perdaems et al., 2010
Sildenafil50500.640.410.5480.748(ichols et al., 2002; Gertz et al., 2010
Triazolam0.250.250.7600.440.8660.508Vanderveen et al., 1991; Kroboth et al., 1995
Celiprolol201000.870d0.2960.8510.348Caruso et al., 1985
Digoxin0.01 (mg/kg)0.750.960.5530.8990.615Rengelshausen et al., 2003; Uchimura et al., 2010
Fexofenadine0.10.10.740.4100.8900.461Lappin et al., 2010
Talinolol301000.941d0.4530.9240.490Wetterich et al., 1996
Indinavir16e4000.840.60.5211.15Yeh et al., 1998, 1999; Gertz et al., 2010
Quinidine400f0.1g0.9190.1600.8480.189Hughes et al., 1975; Ueda et al., 1976; Maeda et al., 2011
1g0.2070.245
Saquinavir126000.740.0070.3170.0221Kupferschmidt et al., 1998; Gertz et al., 2010h;
Verapamil100.1i0.8850.06770.4820.140Fromm et al., 1996; Maeda et al., 2011
3i0.08020.166
  • a Fh was calculated using a hepatic blood flow rate of 25.5 ml/min/kg (Wynne et al., 1989), except for felodipine.

  • b Fh for felodipine was calculated using a hepatic blood flow rate of 43.4 ml/min/kg (Bengtsson-Hasselgren et al., 1990).

  • c Interview form of felodipine (Splendil), AstraZeneca K.K. (Osaka, Japan).

  • d Calculated based on an in silico prediction method (Uchimura et al., 2010).

  • e i.v.-Administered stable isotope compound was taken with 400 mg of unlabeled compound orally.

  • f Dose of quinidine gluconate, including 58.3% of quinidine.

  • g Dose of quinidine sulfate, including 82.9% of quinidine.

  • h Interview form of saquinavir (Invirase), Chugai Pharmaceutical Co., Ltd. (Tokyo, Japan).

  • i Dose of verapamil hydrochloride, including 92.6% of verapamil.